The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
Discovery of the IL-23/IL-17 Signaling Pathway and the Treatment of Psoriasis
Open accessAbstract
Psoriasis vulgaris is a common, heterogeneous, chronic inflammatory skin disease characterized by thickened, red, scaly plaques and systemic inflammation. Psoriasis is also associated with multiple comorbid conditions, such as joint destruction, cardiovascular disease, stroke, hypertension, metabolic syndrome, and chronic kidney disease. The discovery of IL-17–producing T cells in a mouse model of autoimmunity transformed our understanding of inflammation driven by T lymphocytes and associations with human inflammatory diseases, such as psoriasis. Under the regulation of IL-23, T cells that produce high levels of IL-17 create a self-amplifying, feed-forward inflammatory response in keratinocytes that drives the development of thickened skin lesions infiltrated with a mixture of inflammatory cell populations. Recently, the Food and Drug Administration approved multiple highly effective psoriasis therapies that disrupt IL-17 (secukinumab, ixekizumab, and brodalumab) and IL-23 (guselkumab and tildrakizumab) signaling in the skin, thus leading to a major paradigm shift in the way that psoriatic disease is managed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Oppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,822
Innate lymphoid cells — a proposal for uniform nomenclature
Spits, H., Artis, D., Colonna, M., Diefenbach, A., Di Santo, J. P., Eberl, G., Koyasu, S., Locksley, R. M., McKenzie, A. N. J., Mebius, R. E., et al. (2013) · Nature Reviews Immunology · doi:10.1038/nri3365 · Cited by 2,389
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Leonardi, C. L., Kimball, A. B., Papp, K. A., Yeilding, N., Guzzo, C., Wang, Y., Li, S., Dooley, L. T., & Gordon, K. B. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60725-4 · Cited by 1,874
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Pathogenesis and therapy of psoriasis
Lowes, M. A., Bowcock, A. M., & Krueger, J. G. (2007) · Nature · doi:10.1038/nature05663 · Cited by 1,778
Self-citationHueber, W., Sands, B. E., Lewitzky, S., Vandemeulebroecke, M., Reinisch, W., Higgins, P. D. R., Wehkamp, J., Feagan, B. G., Yao, M. D., Karczewski, M., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301668 · Cited by 1,547
Papp, K. A., Langley, R. G., Lebwohl, M., Krueger, G. G., Szapary, P., Yeilding, N., Guzzo, C., Hsu, M.-C., Wang, Y., Li, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60726-6 · Cited by 1,361
A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity
Cella, M., Fuchs, A., Vermi, W., Facchetti, F., Otero, K., Lennerz, J. K. M., Doherty, J. M., Mills, J. C., & Colonna, M. (2009) · Nature · doi:10.1038/nature07537 · Cited by 1,251
Etanercept as Monotherapy in Patients with Psoriasis
Leonardi, C. L., Powers, J. L., Matheson, R. T., Goffe, B. S., Zitnik, R., Wang, A., & Gottlieb, A. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030409 · Cited by 1,175
Psoriasis and comorbid diseases
Takeshita, J., Grewal, S., Langan, S. M., Mehta, N. N., Ogdie, A., Van Voorhees, A. S., & Gelfand, J. M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.07.064 · Cited by 1,145
Psoriasis Vulgaris Lesions Contain Discrete Populations of Th1 and Th17 T Cells
Lowes, M. A., Kikuchi, T., Fuentes-Duculan, J., Cardinale, I., Zaba, L. C., Haider, A. S., Bowman, E. P., & Krueger, J. G. (2008) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5701213 · Cited by 1,082
Self-citationTyring, S., Gottlieb, A., Papp, K., Gordon, K., Leonardi, C., Wang, A., Lalla, D., Woolley, M., Jahreis, A., Zitnik, R., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(05)67763-x · Cited by 1,069
Chronic Mucocutaneous Candidiasis in Humans with Inborn Errors of Interleukin-17 Immunity
Puel, A., Cypowyj, S., Bustamante, J., Wright, J. F., Liu, L., Lim, H. K., Migaud, M., Israel, L., Chrabieh, M., Audry, M., et al. (2011) · Science · doi:10.1126/science.1200439 · Cited by 1,056 · cited 1×
“, chronic mucocutaneous candidiasis) (71) reflects the innate, protective role of this cytokine against”
BackgroundReich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Ferber, I. A., Brocke, S., Taylor-Edwards, C., Ridgway, W., Dinisco, C., Steinman, L., Dalton, D., & Fathman, C. G. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.156.1.5 · Cited by 989
Psoriasis pathogenesis and the development of novel targeted immune therapies
Hawkes, J. E., Chan, T. C., & Krueger, J. G. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.07.004 · Cited by 972
Self-citationWolk, K., Witte, E., Wallace, E., Döcke, W., Kunz, S., Asadullah, K., Volk, H., Sterry, W., & Sabat, R. (2006) · European Journal of Immunology · doi:10.1002/eji.200535503 · Cited by 922
Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
Lin, A. M., Rubin, C. J., Khandpur, R., Wang, J. Y., Riblett, M., Yalavarthi, S., Villanueva, E. C., Shah, P., Kaplan, M. J., & Bruce, A. T. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100123 · Cited by 906
Lee, E., Trepicchio, W. L., Oestreicher, J. L., Pittman, D., Wang, F., Chamian, F., Dhodapkar, M., & Krueger, J. G. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20030451 · Cited by 899
Self-citationBlauvelt, A., Papp, K. A., Griffiths, C. E. M., Randazzo, B., Wasfi, Y., Shen, Y.-K., Li, S., & Kimball, A. B. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.11.041 · Cited by 897
Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial
Menter, A., Tyring, S. K., Gordon, K., Kimball, A. B., Leonardi, C. L., Langley, R. G., Strober, B. E., Kaul, M., Gu, Y., Okun, M., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2007.09.010 · Cited by 889
Comparison of Ustekinumab and Etanercept for Moderate-to-Severe Psoriasis
Griffiths, C. E. M., Strober, B. E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., Guzzo, C., Xia, Y., Zhou, B., Li, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0810652 · Cited by 859
McInnes, I. B., Mease, P. J., Kirkham, B., Kavanaugh, A., Ritchlin, C. T., Rahman, P., van der Heijde, D., Landewé, R., Conaghan, P. G., Gottlieb, A. B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61134-5 · Cited by 858
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis
Gordon, K. B., Blauvelt, A., Papp, K. A., Langley, R. G., Luger, T., Ohtsuki, M., Reich, K., Amato, D., Ball, S. G., Braun, D. K., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1512711 · Cited by 848
Griffiths, C. E. M., Reich, K., Lebwohl, M., van de Kerkhof, P., Paul, C., Menter, A., Cameron, G. S., Erickson, J., Zhang, L., Secrest, R. J., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60125-8 · Cited by 834
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Lebwohl, M., Strober, B., Menter, A., Gordon, K., Weglowska, J., Puig, L., Papp, K., Spelman, L., Toth, D., Kerdel, F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503824 · Cited by 828
McInnes, I. B., Kavanaugh, A., Gottlieb, A. B., Puig, L., Rahman, P., Ritchlin, C., Brodmerkel, C., Li, S., Wang, Y., Mendelsohn, A. M., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60594-2 · Cited by 807
Psoriasis prevalence among adults in the United States
Rachakonda, T. D., Schupp, C. W., & Armstrong, A. W. (2014) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.11.013 · Cited by 783
Reich, K., Armstrong, A. W., Foley, P., Song, M., Wasfi, Y., Randazzo, B., Li, S., Shen, Y.-K., & Gordon, K. B. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.11.042 · Cited by 761
Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis
Mease, P. J., McInnes, I. B., Kirkham, B., Kavanaugh, A., Rahman, P., van der Heijde, D., Landewé, R., Nash, P., Pricop, L., Yuan, J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412679 · Cited by 746
Papp, K. A., Tyring, S., Lahfa, M., Prinz, J., Griffiths, C. E. M., Nakanishi, A. M., Zitnik, R., van de Kerkhof, P. C. M., & the Etanercept Psoriasis Study Group (2005) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2005.06688.x · Cited by 693
Chiricozzi, A., Guttman-Yassky, E., Suárez-Fariñas, M., Nograles, K. E., Tian, S., Cardinale, I., Chimenti, S., & Krueger, J. G. (2011) · Journal of Investigative Dermatology · doi:10.1038/jid.2010.340 · Cited by 686
Self-citationRitchlin, C., Rahman, P., Kavanaugh, A., McInnes, I. B., Puig, L., Li, S., Wang, Y., Shen, Y.-K., Doyle, M. K., Mendelsohn, A. M., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204655 · Cited by 662
Gottlieb, S. L., Gilleaudeau, P., Johnson, R., Estes, L., Woodworth, T. G., Gottlieb, A. B., & Krueger, J. G. (1995) · Nature Medicine · doi:10.1038/nm0595-442 · Cited by 606
Self-citationGottlieb, A. B., Evans, R., Li, S., Dooley, L. T., Guzzo, C. A., Baker, D., Bala, M., Marano, C. W., & Menter, A. (2004) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2004.02.021 · Cited by 581
Mease, P. J., van der Heijde, D., Ritchlin, C. T., Okada, M., Cuchacovich, R. S., Shuler, C. L., Lin, C.-Y., Braun, D. K., Lee, C. H., & Gladman, D. D. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209709 · Cited by 580
Reich, K., Papp, K. A., Blauvelt, A., Tyring, S. K., Sinclair, R., Thaçi, D., Nograles, K., Mehta, A., Cichanowitz, N., Li, Q., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31279-5 · Cited by 569
The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis
Lande, R., Botti, E., Jandus, C., Dojcinovic, D., Fanelli, G., Conrad, C., Chamilos, G., Feldmeyer, L., Marinari, B., Chon, S., et al. (2014) · Nature Communications · doi:10.1038/ncomms6621 · Cited by 539
Up-Regulation of Macrophage Inflammatory Protein-3α/CCL20 and CC Chemokine Receptor 6 in Psoriasis
Homey, B., Dieu-Nosjean, M.-C., Wiesenborn, A., Massacrier, C., Pin, J.-J., Oldham, E., Catron, D., Buchanan, M. E., Müller, A., deWaal Malefyt, R., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.12.6621 · Cited by 537
The Risk of Mortality in Patients With Psoriasis: Results From a Population-Based Study
Gelfand, J. M., Troxel, A. B., Lewis, J. D., Kurd, S. K., Shin, D. B., Wang, X., Margolis, D. J., & Strom, B. L. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.12.1493 · Cited by 533
Boyman, O., Hefti, H. P., Conrad, C., Nickoloff, B. J., Suter, M., & Nestle, F. O. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031482 · Cited by 522
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis
Papp, K. A., Blauvelt, A., Bukhalo, M., Gooderham, M., Krueger, J. G., Lacour, J.-P., Menter, A., Philipp, S., Sofen, H., Tyring, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607017 · Cited by 514
Self-citationHarper, E. G., Guo, C., Rizzo, H., Lillis, J. V., Kurtz, S. E., Skorcheva, I., Purdy, D., Fitch, E., Iordanov, M., & Blauvelt, A. (2009) · Journal of Investigative Dermatology · doi:10.1038/jid.2009.65 · Cited by 508
Loss of T-bet, But Not STAT1, Prevents the Development of Experimental Autoimmune Encephalomyelitis
Bettelli, E., Sullivan, B., Szabo, S. J., Sobel, R. A., Glimcher, L. H., & Kuchroo, V. K. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031819 · Cited by 488
Austin, L. M., Ozawa, M., Kikuchi, T., Walters, I. B., & Krueger, J. G. (1999) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1999.00749.x · Cited by 485
Self-citationPapp, K. A., Reich, K., Paul, C., Blauvelt, A., Baran, W., Bolduc, C., Toth, D., Langley, R. G., Cather, J., Gottlieb, A. B., et al. (2016) · British Journal of Dermatology · doi:10.1111/bjd.14493 · Cited by 470
Self-citationNash, P., Kirkham, B., Okada, M., Rahman, P., Combe, B., Burmester, G.-R., Adams, D. H., Kerr, L., Lee, C., Shuler, C. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31429-0 · Cited by 405
Villanova, F., Flutter, B., Tosi, I., Grys, K., Sreeneebus, H., Perera, G. K., Chapman, A., Smith, C. H., Di Meglio, P., & Nestle, F. O. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.477 · Cited by 386
Targan, S. R., Feagan, B., Vermeire, S., Panaccione, R., Melmed, G. Y., Landers, C., Li, D., Russell, C., Newmark, R., Zhang, N., et al. (2016) · American Journal of Gastroenterology · doi:10.1038/ajg.2016.298 · Cited by 383
Melanocyte antigen triggers autoimmunity in human psoriasis
Arakawa, A., Siewert, K., Stöhr, J., Besgen, P., Kim, S.-M., Rühl, G., Nickel, J., Vollmer, S., Thomas, P., Krebs, S., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20151093 · Cited by 361
Langley, R. G., Tsai, T. ‐., Flavin, S., Song, M., Randazzo, B., Wasfi, Y., Jiang, J., Li, S., & Puig, L. (2018) · British Journal of Dermatology · doi:10.1111/bjd.15750 · Cited by 341
Teunissen, M. B. M., Munneke, J. M., Bernink, J. H., Spuls, P. I., Res, P. C. M., te Velde, A., Cheuk, S., Brouwer, M. W. D., Menting, S. P., Eidsmo, L., et al. (2014) · Journal of Investigative Dermatology · doi:10.1038/jid.2014.146 · Cited by 335
Long-term Safety and Efficacy of 50 mg of Etanercept Twice Weekly in Patients With Psoriasis
Tyring, S., Gordon, K. B., Poulin, Y., Langley, R. G., Gottlieb, A. B., Dunn, M., & Jahreis, A. (2007) · Archives of Dermatology · doi:10.1001/archderm.143.6.719 · Cited by 324
Scanning the Immunopathogenesis of Psoriasis
Chiricozzi, A., Romanelli, P., Volpe, E., Borsellino, G., & Romanelli, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19010179 · Cited by 320
Conrad, C., Di Domizio, J., Mylonas, A., Belkhodja, C., Demaria, O., Navarini, A. A., Lapointe, A.-K., French, L. E., Vernez, M., & Gilliet, M. (2018) · Nature Communications · doi:10.1038/s41467-017-02466-4 · Cited by 317
Blauvelt, A., Reich, K., Tsai, T.-F., Tyring, S., Vanaclocha, F., Kingo, K., Ziv, M., Pinter, A., Vender, R., Hugot, S., et al. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.08.008 · Cited by 312
Lew, W., Bowcock, A. M., & Krueger, J. G. (2004) · Trends in Immunology · doi:10.1016/j.it.2004.03.006 · Cited by 284
Self-citationGlatt, S., Baeten, D., Baker, T., Griffiths, M., Ionescu, L., Lawson, A. D. G., Maroof, A., Oliver, R., Popa, S., Strimenopoulou, F., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212127 · Cited by 270
Gudjonsson, J. E., Johnston, A., Dyson, M., Valdimarsson, H., & Elder, J. T. (2007) · Journal of Investigative Dermatology · doi:10.1038/sj.jid.5700807 · Cited by 266
Cheung, K. L., Jarrett, R., Subramaniam, S., Salimi, M., Gutowska-Owsiak, D., Chen, Y.-L., Hardman, C., Xue, L., Cerundolo, V., & Ogg, G. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160258 · Cited by 249
Ottaviani, C., Nasorri, F., Bedini, C., de Pità, O., Girolomoni, G., & Cavani, A. (2006) · European Journal of Immunology · doi:10.1002/eji.200535243 · Cited by 248
Wang, C. Q. F., Akalu, Y. T., Suarez-Farinas, M., Gonzalez, J., Mitsui, H., Lowes, M. A., Orlow, S. J., Manga, P., & Krueger, J. G. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.237 · Cited by 232
Self-citationPsoriasis and comorbid diseases
Takeshita, J., Grewal, S., Langan, S. M., Mehta, N. N., Ogdie, A., Van Voorhees, A. S., & Gelfand, J. M. (2017) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2016.07.065 · Cited by 226
Cutting Edge: A Critical Functional Role for IL-23 in Psoriasis
Tonel, G., Conrad, C., Laggner, U., Di Meglio, P., Grys, K., McClanahan, T. K., Blumenschein, W. M., Qin, J.-Z., Xin, H., Oldham, E., et al. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001538 · Cited by 224
Expression of Interleukin-12 is Increased in Psoriatic Skin
Yawalkar, N., Karlen, S., Hunger, R., Brand, C. U., & Braathen, L. R. (1998) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.1998.00446.x · Cited by 221
Bonish, B., Jullien, D., Dutronc, Y., Huang, B. B., Modlin, R., Spada, F. M., Porcelli, S. A., & Nickoloff, B. J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.7.4076 · Cited by 220
IL-12 protects from psoriasiform skin inflammation
Kulig, P., Musiol, S., Freiberger, S. N., Schreiner, B., Gyülveszi, G., Russo, G., Pantelyushin, S., Kishihara, K., Alessandrini, F., Kündig, T., et al. (2016) · Nature Communications · doi:10.1038/ncomms13466 · Cited by 197
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials
Lebwohl, M. G., Papp, K. A., Marangell, L. B., Koo, J., Blauvelt, A., Gooderham, M., Wu, J. J., Rastogi, S., Harris, S., Pillai, R., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.08.024 · Cited by 179
Haider, A. S., Lowes, M. A., Suárez-Fariñas, M., Zaba, L. C., Cardinale, I., Khatcherian, A., Novitskaya, I., Wittkowski, K. M., & Krueger, J. G. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.3.1913 · Cited by 173
Self-citationGottlieb, A. B., Blauvelt, A., Thaçi, D., Leonardi, C. L., Poulin, Y. P., Drew, J., Peterson, L., Arendt, C. H., Burge, D. J., & Reich, K. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.012 · Cited by 157
Constantinescu, C. S., Wysocka, M., Hilliard, B. A., Ventura, E. S., Lavi, E., Trinchieri, G., & Rostami, A. M. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.9.5097 · Cited by 144
IL-29 Is Produced by T H 17 Cells and Mediates the Cutaneous Antiviral Competence in Psoriasis
Wolk, K., Witte, K., Witte, E., Raftery, M., Kokolakis, G., Philipp, S., Schönrich, G., Warszawska, K., Kirsch, S., Prösch, S., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006245 · Cited by 136
Lebwohl, M., Blauvelt, A., Paul, C. F., Sofen, H. L., Węgłowska, J., Piguet, V., Burge, D. J., Rolleri, R., Drew, J., Peterson, L., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2018.04.013 · Cited by 134
Nickoloff, B. J., Bonish, B. K., Huang, B. B., & Porcelli, S. A. (2000) · Journal of Dermatological Science · doi:10.1016/s0923-1811(00)00120-1 · Cited by 129
Humanized anti–IFN-γ (HuZAF) in the treatment of psoriasis
Harden, J. L., Johnson-Huang, L. M., Chamian, F., Lee, E., Pearce, T. E., Leonardi, C. L., Haider, A. S., Lowes, M. A., & Krueger, J. G. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.05.046 · Cited by 118
Self-citationSexy again: the renaissance of neutrophils in psoriasis
Schön, M. P., Broekaert, S. M. C., & Erpenbeck, L. (2016) · Experimental Dermatology · doi:10.1111/exd.13067 · Cited by 91
Victor, E. S., Fickenscher, H., & Bayry, J. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005624 · Cited by 79
Research Techniques Made Simple: Murine Models of Human Psoriasis
Hawkes, J. E., Aðalsteinsson, J. A., Gudjonsson, J. E., & Ward, N. L. (2017) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2017.10.013 · Cited by 71
Self-citationA revolutionary therapeutic approach for psoriasis: bispecific biological agents
Torres, T., Romanelli, M., & Chiricozzi, A. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1187130 · Cited by 54
Stoffel, E., Maier, H., Riedl, E., Brüggen, M., Reininger, B., Schaschinger, M., Bangert, C., Guenova, E., Stingl, G., & Brunner, P. M. (2017) · British Journal of Dermatology · doi:10.1111/bjd.16126 · Cited by 51
Ustekinumab in the treatment of psoriatic arthritis: latest findings and clinical potential
Gottlieb, A. B., & Narang, K. (2013) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x13501021 · Cited by 47
Neutrophils are not the dominant interleukin‐17 producer in psoriasis
Yamanaka, K., Yamagiwa, A., Akeda, T., Kondo, M., Kakeda, M., Habe, K., Imafuku, S., Sano, S., & Mizutani, H. (2017) · The Journal of Dermatology · doi:10.1111/1346-8138.13807 · Cited by 12
Cited by
Advances in the pathogenesis of psoriasis: from keratinocyte perspective
Zhou, X., Chen, Y., Cui, L., Shi, Y., & Guo, C. (2022) · Cell Death & Disease · doi:10.1038/s41419-022-04523-3 · Cited by 632
Interleukin-17A and Keratinocytes in Psoriasis
Furue, M., Furue, K., Tsuji, G., & Nakahara, T. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21041275 · Cited by 300
IL-12 Family Cytokines in Cancer and Immunotherapy
Mirlekar, B., & Pylayeva-Gupta, Y. (2021) · Cancers · doi:10.3390/cancers13020167 · Cited by 295
Crosstalk of Inflammatory Cytokines within the Breast Tumor Microenvironment
Habanjar, O., Bingula, R., Decombat, C., Diab-Assaf, M., Caldefie-Chezet, F., & Delort, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044002 · Cited by 263
Resident Memory T Cells in Autoimmune Skin Diseases
Ryan, G. E., Harris, J. E., & Richmond, J. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.652191 · Cited by 132
Metadata
- Authors
- Hawkes, J. E., Yan, B. Y., Chan, T. C., & Krueger, J. G.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2018-09
- Volume
- 201
- Issue
- 6
- Pages
- 1605-1613
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2890147164
- Cited by
- 593
- References
- 85
- FWCI
- 17.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.